| scholarly article | Q13442814 |
| P2093 | author name string | Lang J | |
| Wallace D | |||
| Chanthavanich P | |||
| Sabchareon A | |||
| Pengsaa K | |||
| Sirivichayakul C | |||
| Tornieporth NG | |||
| Viviani S | |||
| Suvannadabba S | |||
| Bouckenooghe A | |||
| Limkittikul K | |||
| Saville M | |||
| Dulyachai W | |||
| Jiwariyavej V | |||
| Moureau A | |||
| Wartel TA | |||
| P2860 | cites work | Dengue | Q24570132 |
| From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine | Q24737418 | ||
| Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates | Q27469664 | ||
| The Epidemiology of Dengue in the Americas Over the Last Three Decades: A Worrisome Reality | Q27490789 | ||
| Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards | Q28476176 | ||
| Development and evaluation of serotype- and group-specific fluorogenic reverse transcriptase PCR (TaqMan) assays for dengue virus. | Q30757311 | ||
| Emergence of the Asian 1 genotype of dengue virus serotype 2 in viet nam: in vivo fitness advantage and lineage replacement in South-East Asia | Q33638366 | ||
| Dengue infection in children in Ratchaburi, Thailand: a cohort study. II. Clinical manifestations | Q34184722 | ||
| Dengue infection in children in Ratchaburi, Thailand: a cohort study. I. Epidemiology of symptomatic acute dengue infection in children, 2006-2009. | Q34364955 | ||
| Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore | Q36631286 | ||
| Guidelines for Plaque-Reduction Neutralization Testing of Human Antibodies to Dengue Viruses | Q37162404 | ||
| Vaccines for the prevention of dengue: development update | Q37867401 | ||
| Dengue vaccines: progress and challenges | Q37868122 | ||
| Critical issues in dengue vaccine development | Q37907783 | ||
| Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines | Q38931449 | ||
| Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses | Q39357324 | ||
| Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru | Q40278672 | ||
| Population dynamics of DENV-1 genotype V in Brazil is characterized by co-circulation and strain/lineage replacement | Q40281096 | ||
| Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity | Q40344756 | ||
| Guidelines for clinical trials of dengue vaccine in endemic areas | Q40378139 | ||
| The use of dengue nonstructural protein 1 antigen for the early diagnosis during the febrile stage in patients with dengue infection | Q40430989 | ||
| The economic burden of dengue | Q43151069 | ||
| P433 | issue | 9853 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Thailand | Q869 |
| vaccine | Q134808 | ||
| Dengue virus | Q476209 | ||
| attenuated vaccine | Q1810913 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1559-67 | |
| P577 | publication date | 2012-11-03 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial | |
| P478 | volume | 380 |
| Q39375092 | A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis. |
| Q42977175 | A Promising, Single-Dose, Live Attenuated Tetravalent Dengue Vaccine Candidate |
| Q89552802 | A Review on Dengue Vaccine Development |
| Q39023333 | A Tetravalent Formulation Based on Recombinant Nucleocapsid-like Particles from Dengue Viruses Induces a Functional Immune Response in Mice and Monkeys. |
| Q35011189 | A birth cohort study of viral infections in Vietnamese infants and children: study design, methods and characteristics of the cohort |
| Q37336762 | A chimeric dengue virus vaccine using Japanese encephalitis virus vaccine strain SA14-14-2 as backbone is immunogenic and protective against either parental virus in mice and nonhuman primates |
| Q26824776 | A critical assessment of vector control for dengue prevention |
| Q40061824 | A dose-response study in mice of a tetravalent vaccine candidate composed of domain III-capsid proteins from dengue viruses |
| Q39811978 | A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease |
| Q35654743 | A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus |
| Q35652132 | A new moment for facing dengue? |
| Q38786420 | A novel dengue virus serotype 1 vaccine candidate based on Japanese encephalitis virus vaccine strain SA14-14-2 as the backbone |
| Q39500706 | A novel tetravalent formulation combining the four aggregated domain III-capsid proteins from dengue viruses induces a functional immune response in mice and monkeys |
| Q38987775 | A nuclear transport inhibitor that modulates the unfolded protein response and provides in vivo protection against lethal dengue virus infection. |
| Q28241909 | A rapid immunization strategy with a live-attenuated tetravalent dengue vaccine elicits protective neutralizing antibody responses in non-human primates |
| Q38738484 | A recombinant live attenuated tetravalent vaccine for the prevention of dengue |
| Q38658737 | A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone |
| Q90560585 | A review of Dengvaxia®: development to deployment |
| Q38184218 | A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available |
| Q36607295 | A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial |
| Q35082478 | A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture |
| Q35806060 | A tetravalent alphavirus-vector based dengue vaccine provides effective immunity in an early life mouse model |
| Q38157807 | Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue |
| Q40122469 | Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine |
| Q35272502 | An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques |
| Q36667964 | An alphavirus vector-based tetravalent dengue vaccine induces a rapid and protective immune response in macaques that differs qualitatively from immunity induced by live virus infection |
| Q37123147 | An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody |
| Q40210664 | An intact signal peptide on dengue virus E protein enhances immunogenicity for CD8(+) T cells and antibody when expressed from modified vaccinia Ankara |
| Q97521587 | Anti-dengue Vaccines: From Development to Clinical Trials |
| Q35168403 | Antibodies against immature virions are not a discriminating factor for dengue disease severity |
| Q38825543 | Antibodies are not required to a protective immune response against dengue virus elicited in a mouse encephalitis model |
| Q40096637 | Apoptosis-related genes control autophagy and influence DENV-2 infection in the mosquito vector, Aedes aegypti |
| Q35162542 | Aptamer Displacement Screen for Flaviviral RNA Methyltransferase Inhibitors |
| Q56797968 | Ask the Experts: Surveillance of global dengue distribution |
| Q92650511 | Assessing the Diversity and Stability of Cellular Immunity Generated in Response to the Candidate Live-Attenuated Dengue Virus Vaccine TAK-003 |
| Q33723518 | Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico |
| Q26746185 | Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment |
| Q38081702 | Beyond insecticides: new thinking on an ancient problem |
| Q61809674 | Biased efficacy estimates in phase-III dengue vaccine trials due to heterogeneous exposure and differential detectability of primary infections across trial arms |
| Q46320575 | Bifurcation thresholds and optimal control in transmission dynamics of arboviral diseases. |
| Q40040211 | Biodistribution and safety of a live attenuated tetravalent dengue vaccine in the cynomolgus monkey |
| Q29994527 | Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond |
| Q38352326 | Building the Human Vaccines Project: strategic management recommendations and summary report of the 15-16 July 2014 business workshop |
| Q33841059 | Burden of dengue infection and disease in a pediatric cohort in urban Sri Lanka |
| Q35760439 | CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice |
| Q39085489 | CYD-TDV dengue vaccine: systematic review and meta-analysis of efficacy, immunogenicity and safety |
| Q42548722 | Call to action for dengue vaccine failure |
| Q90050612 | Can Complementary Prime-Boost Immunization Strategies Be an Alternative and Promising Vaccine Approach Against Dengue Virus? |
| Q35180143 | Capsid protein: evidences about the partial protective role of neutralizing antibody-independent immunity against dengue in monkeys |
| Q28068972 | Cell-targeting antibodies in immunity to Ebola |
| Q36263779 | Cellular Immune Responses to Live Attenuated Japanese Encephalitis (JE) Vaccine SA14-14-2 in Adults in a JE/Dengue Co-Endemic Area. |
| Q28547173 | Cellular promyelocytic leukemia protein is an important dengue virus restriction factor |
| Q38159976 | Central nervous system infections in travelers |
| Q38121757 | Challenges for the formulation of a universal vaccine against dengue. |
| Q38140035 | Challenges in reducing dengue burden; diagnostics, control measures and vaccines |
| Q34979888 | Challenges in the interpretation of dengue vaccine trial results |
| Q33431345 | Characterization of dengue virus 2 growth in megakaryocyte-erythrocyte progenitor cells |
| Q59349143 | Characterization of recombinant yellow fever-dengue vaccine viruses with human monoclonal antibodies targeting key conformational epitopes |
| Q30365058 | Characterization of the mode of action of a potent dengue virus capsid inhibitor |
| Q34637823 | Circulation of different lineages of Dengue virus 2, genotype American/Asian in Brazil: dynamics and molecular and phylogenetic characterization |
| Q28551786 | Cissampelos pareira Linn: Natural Source of Potent Antiviral Activity against All Four Dengue Virus Serotypes |
| Q38616705 | Clinical Efficacy, Safety, and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine (CYD-TDV) in Children: A Systematic Review with Meta-analysis |
| Q34428943 | Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial |
| Q33841065 | Clinical presentation of dengue by serotype and year of epidemic in Martinique |
| Q34261496 | Combined effects of the structural heterogeneity and dynamics of flaviviruses on antibody recognition |
| Q33943479 | Comparing dengue and chikungunya emergence and endemic transmission in A. aegypti and A. albopictus |
| Q30145660 | Comparison of Two Detailed Models of Aedes aegypti Population Dynamics |
| Q39535403 | Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development |
| Q35758626 | Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies |
| Q36895622 | Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells |
| Q37642687 | Conformational changes in intact dengue virus reveal serotype-specific expansion |
| Q91807708 | Considering Genomic and Immunological Correlates of Protection for a Dengue Intervention |
| Q40198029 | Construction and preliminary investigation of a novel dengue serotype 4 chimeric virus using Japanese encephalitis vaccine strain SA14-14-2 as the backbone |
| Q91209749 | Construction of a novel tetravalent dengue vaccine with a Salmonella Typhimurium bacterial ghost and evaluation of its immunogenicity and protective efficacy using a murine model |
| Q30361791 | Consultation on dengue vaccines: progress in understanding protection, 26-28 June 2013, Rockville, Maryland. |
| Q21562250 | Controlling dengue with vaccines in Thailand |
| Q35864468 | Cooperation between CD4+ T Cells and Humoral Immunity Is Critical for Protection against Dengue Using a DNA Vaccine Based on the NS1 Antigen |
| Q34779065 | Correlation between dengue-specific neutralizing antibodies and serum avidity in primary and secondary dengue virus 3 natural infections in humans |
| Q35590817 | Correlation between serum levels of anti-endothelial cell autoantigen and anti-dengue virus nonstructural protein 1 antibodies in dengue patients |
| Q39326565 | Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission |
| Q40130106 | Could an experimental dengue virus infection fail to induce solid immunity against homologous viral challenge in non-human primates? |
| Q37625631 | Country- and age-specific optimal allocation of dengue vaccines |
| Q28656187 | Coverage-dependent effect of insecticide-treated curtains for dengue control in Thailand |
| Q40093858 | Critique of World Health Organization Recommendation of a Dengue Vaccine |
| Q66679685 | Cross-Reactive T Cell Immunity to Dengue and Zika Viruses: New Insights Into Vaccine Development |
| Q38661075 | Current issues in the economics of vaccination against dengue |
| Q33408300 | Current progress in dengue vaccines |
| Q34788758 | Current trends in West Nile virus vaccine development |
| Q28079626 | Cytotoxic CD4 T Cells: Differentiation, Function, and Application to Dengue Virus Infection |
| Q26822466 | Deconstructing "malaria": West Africa as the next front for dengue fever surveillance and control |
| Q91711499 | Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade |
| Q85389327 | Defeating dengue: a challenge for a vaccine |
| Q91341741 | Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine |
| Q59349881 | Delineating the serotype-specific neutralizing antibody response to a live attenuated tetravalent dengue vaccine |
| Q85327578 | Dengue |
| Q27304342 | Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes |
| Q26700082 | Dengue Fever: Causes, Complications, and Vaccine Strategies |
| Q91688064 | Dengue Mosaic Vaccines Enhance Cellular Immunity and Expand the Breadth of Neutralizing Antibody Against All Four Serotypes of Dengue Viruses in Mice |
| Q90829180 | Dengue NS2A Protein Orchestrates Virus Assembly |
| Q36745257 | Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection |
| Q26247258 | Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus |
| Q35641391 | Dengue Virus Evolution under a Host-Targeted Antiviral |
| Q35817119 | Dengue Virus Infection of Aedes aegypti Requires a Putative Cysteine Rich Venom Protein |
| Q35641205 | Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice. |
| Q24290837 | Dengue and dengue vectors in the WHO European region: past, present, and scenarios for the future |
| Q40243587 | Dengue dynamics and vaccine cost-effectiveness in Brazil. |
| Q42963067 | Dengue fever in China: an emerging problem demands attention |
| Q38268430 | Dengue fever in Europe: could there be an epidemic in the future? |
| Q33951512 | Dengue human infection model performance parameters |
| Q33724565 | Dengue human infection model: introduction |
| Q39521661 | Dengue human infection model: re-establishing a tool for understanding dengue immunology and advancing vaccine development |
| Q39590469 | Dengue human infection models supporting drug development |
| Q38386336 | Dengue human infection models to advance dengue vaccine development |
| Q34496111 | Dengue seroprevalence and risk factors for past and recent viral transmission in Venezuela: a comprehensive community-based study |
| Q55046089 | Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005-2014). |
| Q37270826 | Dengue serotype immune-interactions and their consequences for vaccine impact predictions |
| Q27677270 | Dengue structure differs at the temperatures of its human and mosquito hosts |
| Q28542607 | Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions |
| Q88536628 | Dengue vaccination during pregnancy - An overview of clinical trials data |
| Q36208955 | Dengue vaccine acceptance and willingness to pay. |
| Q40274567 | Dengue vaccine development: a 75% solution? |
| Q53158319 | Dengue vaccine development: challenges and emerging opportunities |
| Q40256702 | Dengue vaccine efficacy trial: does interference cause failure? |
| Q38772532 | Dengue vaccine safety signal: Immune enhancement, waning immunity, or chance occurrence? |
| Q47562022 | Dengue vaccine-induced CD8+ T cell immunity confers protection in the context of enhancing, interfering maternal antibodies |
| Q26314686 | Dengue vaccine: a valuable asset for the future |
| Q42985743 | Dengue vaccine: hypotheses to understand CYD-TDV-induced protection |
| Q40200462 | Dengue vaccines: dawning at last? |
| Q34367194 | Dengue vaccines: recent developments, ongoing challenges and current candidates |
| Q35008771 | Dengue vaccines: strongly sought but not a reality just yet |
| Q38960985 | Dengue vaccines: what we know, what has been done, but what does the future hold? |
| Q40198181 | Dengue virus and host antibody: a dangerous balancing act. |
| Q37571377 | Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity |
| Q43038900 | Dengue virus envelope protein domain I/II hinge: a key target for dengue virus vaccine design? |
| Q34746693 | Dengue virus neutralization in cells expressing Fc gamma receptors |
| Q34351011 | Dengue virus neutralizing antibody levels associated with protection from infection in thai cluster studies |
| Q37694855 | Dengue virus photo-inactivated in presence of 1,5-iodonaphthylazide (INA) or AMT, a psoralen compound (4'-aminomethyl-trioxsalen) is highly immunogenic in mice |
| Q34718200 | Dengue virus type 3 adaptive changes during epidemics in São Jose de Rio Preto, Brazil, 2006-2007. |
| Q40207674 | Dengue virus-infected human dendritic cells reveal hierarchies of naturally expressed novel NS3 CD8 T cell epitopes |
| Q40246811 | Dengue virus: two hosts, two structures |
| Q36926525 | Dengue viruses cluster antigenically but not as discrete serotypes |
| Q58112353 | Dengue-2 virus-like particle (VLP) based vaccine elicits the highest titers of neutralizing antibodies when produced at reduced temperature |
| Q40246595 | Dengue-specific subviral nanoparticles: design, creation and characterization |
| Q40215531 | Dengue: "plus ça change, plus c'est la même chose". |
| Q27010609 | Dengue: Moving from Current Standard of Care to State-of-the-Art Treatment |
| Q28085044 | Dengue: an update on treatment options |
| Q33624327 | Dengue: challenges for policy makers and vaccine developers |
| Q28729764 | Dengue: knowledge gaps, unmet needs, and research priorities |
| Q92942083 | Design and production of dengue virus chimeric proteins useful for developing tetravalent vaccines |
| Q38877746 | Detection of dengue cases by serological testing in a dengue vaccine efficacy trial: Utility for efficacy evaluation and impact of future vaccine introduction |
| Q40052993 | Detection, phenotyping and quantification of dengue virus-specific B cells using fluorescent probes |
| Q38201151 | Developing a dengue vaccine: progress and future challenges |
| Q40038715 | Development of Peptide Vaccines in Dengue. |
| Q37115807 | Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine? |
| Q59337373 | Development of standard clinical endpoints for use in dengue interventional trials: introduction and methodology |
| Q38609515 | Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward |
| Q37643762 | Dimerization of flavivirus NS4B protein |
| Q35643850 | Discovery of Dengue Virus NS4B Inhibitors |
| Q56344671 | Discovery of Immunologically Inspired Small Molecules That Target the Viral Envelope Protein |
| Q24736845 | Discovery of fifth serotype of dengue virus (DENV-5): A new public health dilemma in dengue control |
| Q38727029 | Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals. |
| Q33728716 | Dissecting the human serum antibody response to secondary dengue virus infections |
| Q37089546 | Dogma in classifying dengue disease |
| Q88600750 | EMERGING RESPIRATORY DISEASE - CORONAVIRUSES |
| Q59356878 | Early Transcriptional Responses After Dengue Vaccination Mirror the Response to Natural Infection and Predict Neutralizing Antibody Titers |
| Q27303669 | Early Transcriptional Signatures of the Immune Response to a Live Attenuated Tetravalent Dengue Vaccine Candidate in Non-human Primates |
| Q34422058 | Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial |
| Q86508002 | Efficacy of tetravalent dengue vaccine in Thai schoolchildren |
| Q95524755 | Efficacy of tetravalent dengue vaccine in Thai schoolchildren |
| Q44039929 | Efficacy of tetravalent dengue vaccine in Thai schoolchildren - Authors' reply |
| Q63246344 | Efficacy, immunogenicity and safety of a recombinant tetravalent dengue vaccine (CYD-TDV) in children aged 2-17 years: systematic review and meta-analysis |
| Q33959381 | Elucidating the role of T cells in protection against and pathogenesis of dengue virus infections |
| Q36756643 | Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity |
| Q61053647 | Emerging and Reemerging Aedes-Transmitted Arbovirus Infections in the Region of the Americas: Implications for Health Policy |
| Q28654939 | Enhancing the work of the Department of Health and Human Services national vaccine program in global immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on September 12, 2013 |
| Q36663377 | Epidemiological determinants of successful vaccine development |
| Q35866928 | Epidemiology of Infant Dengue Cases Illuminates Serotype-Specificity in the Interaction between Immunity and Disease, and Changes in Transmission Dynamics |
| Q35448628 | Estimating dengue transmission intensity from sero-prevalence surveys in multiple countries. |
| Q28652179 | Estimation of Aedes aegypti (Diptera: Culicidae) population size and adult male survival in an urban area in Panama |
| Q40081496 | Estimation of parameters related to vaccine efficacy and dengue transmission from two large phase III studies |
| Q97565389 | Ethics of a partially effective dengue vaccine: Lessons from the Philippines |
| Q33412959 | Evaluation of dengue virus strains for human challenge studies. |
| Q34522384 | Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates. |
| Q39611330 | Evaluation of single-round infectious, chimeric dengue type 1 virus as an antigen for dengue functional antibody assays |
| Q29365799 | Exploiting virus-like particles as innovative vaccines against emerging viral infections |
| Q39611325 | Expression of enhancing-activity-free neutralizing antibody against dengue type 1 virus in plasmid-inoculated mice |
| Q33590655 | Fever and rash in a woman returning from the Caribbean |
| Q47560369 | Field- and clinically derived estimates of Wolbachia-mediated blocking of dengue virus transmission potential in Aedes aegypti mosquitoes |
| Q38086052 | Fight against dengue in India: progresses and challenges |
| Q38184248 | Flavivirus RNA methylation |
| Q55519030 | Flavivirus serocomplex cross-reactive immunity is protective by activating heterologous memory CD4 T cells. |
| Q36878970 | Functional Transplant of a Dengue Virus Serotype 3 (DENV3)-Specific Human Monoclonal Antibody Epitope into DENV1. |
| Q37123259 | Functional analysis of antibodies against dengue virus type 4 reveals strain-dependent epitope exposure that impacts neutralization and protection |
| Q38201317 | Functional interplay among the flavivirus NS3 protease, helicase, and cofactors |
| Q39126155 | Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage. |
| Q40138769 | Generation and preclinical immunogenicity study of dengue type 2 virus-like particles derived from stably transfected mosquito cells |
| Q37726480 | Genetic control of Aedes mosquitoes |
| Q39375868 | Genetic epidemiology of dengue viruses in phase III trials of the CYD tetravalent dengue vaccine and implications for efficacy |
| Q28073351 | Genomic approaches for understanding dengue: insights from the virus, vector, and host |
| Q24736362 | Global spread of dengue virus types: mapping the 70 year history |
| Q26782367 | Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine |
| Q34016119 | Heterogeneous feeding patterns of the dengue vector, Aedes aegypti, on individual human hosts in rural Thailand |
| Q37336440 | High-avidity and potently neutralizing cross-reactive human monoclonal antibodies derived from secondary dengue virus infection |
| Q33852796 | Highly efficient production of a dengue pseudoinfectious virus |
| Q63246508 | Homologs of Human Dengue-Resistance Genes, and , Confer Antiviral Resistance in Mosquitoes |
| Q36895627 | Host and viral features of human dengue cases shape the population of infected and infectious Aedes aegypti mosquitoes |
| Q34630542 | Host cell transcriptome profile during wild-type and attenuated dengue virus infection |
| Q36545428 | House-to-house human movement drives dengue virus transmission |
| Q33853984 | How season and serotype determine dengue transmissibility |
| Q36250195 | Human CD8+ T-Cell Responses Against the 4 Dengue Virus Serotypes Are Associated With Distinct Patterns of Protein Targets |
| Q90266052 | Human T Cell Response to Dengue Virus Infection |
| Q26314609 | Human antibody response to dengue virus: implications for dengue vaccine design |
| Q37735002 | Human immune responses to dengue virus infection: lessons learned from prospective cohort studies |
| Q36846290 | Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics |
| Q40043632 | Humanized mouse models to study human cell-mediated and humoral responses to dengue virus |
| Q35743398 | Hybrid flagellin as a T cell independent vaccine scaffold |
| Q33679954 | Hypoxia enhances antibody-dependent dengue virus infection |
| Q35018972 | Identification of conserved and HLA promiscuous DENV3 T-cell epitopes |
| Q61795459 | Identification of small molecule inhibitors targeting the Zika virus envelope protein |
| Q38125045 | Identifying protective dengue vaccines: guide to mastering an empirical process |
| Q33924674 | Immune correlates for dengue vaccine development |
| Q34261827 | Immunodominance changes as a function of the infecting dengue virus serotype and primary versus secondary infection |
| Q92001054 | Immunodomination of Serotype-Specific CD4+ T-Cell Epitopes Contributed to the Biased Immune Responses Induced by a Tetravalent Measles-Vectored Dengue Vaccine |
| Q40140203 | Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus |
| Q35548048 | Immunogenicity and efficacy of flagellin-envelope fusion dengue vaccines in mice and monkeys |
| Q37372595 | Immunogenicity and safety of a recombinant tetravalent dengue vaccine in children and adolescents ages 9-16 years in Brazil |
| Q27468578 | Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial |
| Q47584703 | Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2-17 years in Asia and Latin America: 18-month interim data from a phase 2, randomised, placebo-controlled study. |
| Q102206092 | Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study |
| Q58367209 | Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults |
| Q47209860 | Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials |
| Q39141627 | Impact of combined vector-control and vaccination strategies on transmission dynamics of dengue fever: a model-based analysis. |
| Q51733262 | Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4. |
| Q30250977 | In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination |
| Q66679185 | In vitro and in silico Models to Study Mosquito-Borne Flavivirus Neuropathogenesis, Prevention, and Treatment |
| Q40224356 | In vitro evaluation of novel inhibitors against the NS2B-NS3 protease of dengue fever virus type 4. |
| Q28550030 | Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru |
| Q30847507 | Increased replicative fitness of a dengue virus 2 clade in native mosquitoes: potential contribution to a clade replacement event in Nicaragua |
| Q38990899 | Increasing Complexity of Vaccine Development |
| Q33332171 | Incubation Periods of Mosquito-Borne Viral Infections: A Systematic Review |
| Q37500519 | Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine |
| Q33699057 | Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines |
| Q36363799 | Infectious dengue vesicles derived from CD61+ cells in acute patient plasma exhibited a diaphanous appearance |
| Q40124689 | Influence of FcγRIIa-Expressing Cells on the Assessment of Neutralizing and Enhancing Serum Antibodies Elicited by a Live-Attenuated Tetravalent Dengue Vaccine |
| Q90024871 | Inhibition of dengue virus replication in monocyte-derived dendritic cells by vivo-morpholino oligomers |
| Q36748027 | Innate immune sensing of HIV-1 by dendritic cells |
| Q43038353 | Insecticidal activity and expression of cytochrome P450 family 4 genes in Aedes albopictus after exposure to pyrethroid mosquito coils |
| Q47224202 | Insecticide treated curtains and residual insecticide treatment to control Aedes aegypti: An acceptability study in Santiago de Cuba |
| Q38734455 | Integrated immunogenicity analysis of a tetravalent dengue vaccine up to 4 y after vaccination |
| Q35952111 | Integrating Transgenic Vector Manipulation with Clinical Interventions to Manage Vector-Borne Diseases |
| Q37062703 | Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity |
| Q58704978 | Interferon-stimulated TRIM69 interrupts dengue virus replication by ubiquitinating viral nonstructural protein 3 |
| Q59354754 | Interleukin-33 contributes to disease severity in Dengue virus infection in mice |
| Q26823330 | Introducing a dengue vaccine to Mexico: development of a system for evidence-based public policy recommendations |
| Q63246464 | Key Amino Acid Substitution for Infection-Enhancing Activity-Free Designer Dengue Vaccines |
| Q38618056 | Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates? |
| Q33424504 | Laboratory-confirmed Dengue in Children in Three Regional Hospitals in the Philippines in 2009-2010. |
| Q27023422 | Latest developments and future directions in dengue vaccines |
| Q85637749 | Lessons from vaccine history |
| Q35109193 | Limited dengue virus replication in field-collected Aedes aegypti mosquitoes infected with Wolbachia |
| Q34999863 | Lipidated dengue-2 envelope protein domain III independently stimulates long-lasting neutralizing antibodies and reduces the risk of antibody-dependent enhancement |
| Q33743890 | Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination |
| Q42998710 | Live attenuated vaccine: the first clinically approved dengue vaccine? |
| Q36307457 | Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment |
| Q37706823 | Long-term safety assessment of live attenuated tetravalent dengue vaccines: deliberations from a WHO technical consultation |
| Q40142974 | Lot-to-lot consistency of a tetravalent dengue vaccine in healthy adults in Australia: a randomised study. |
| Q37130999 | Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees |
| Q39084398 | Lyso-myristoyl phosphatidylcholine micelles sustain the activity of Dengue non-structural (NS) protein 3 protease domain fused with the full-length NS2B. |
| Q38945522 | Machine learning methods enable predictive modeling of antibody feature:function relationships in RV144 vaccinees |
| Q35065031 | Male mosquitoes as vehicles for insecticide |
| Q35488254 | Mapping the Interactions between the NS4B and NS3 proteins of dengue virus |
| Q23032973 | Mechanism and significance of cell type-dependent neutralization of flaviviruses |
| Q57812953 | Memory T Cells in Flavivirus Vaccination |
| Q40530597 | Modeling the Role of Epitope Arrangement on Antibody Binding Stoichiometry in Flaviviruses |
| Q35326145 | Modeling the impact on virus transmission of Wolbachia-mediated blocking of dengue virus infection of Aedes aegypti |
| Q40243226 | Modelling interventions during a dengue outbreak |
| Q35856554 | Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia |
| Q38120526 | Multiantibody strategies for HIV. |
| Q28296618 | Neurological complications of dengue virus infection |
| Q89453187 | Neutralizing Antibody Correlates Analysis of Tetravalent Dengue Vaccine Efficacy Trials in Asia and Latin America |
| Q36498207 | Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort |
| Q35058877 | Neutralizing dengue antibody in pregnant Thai women and cord blood |
| Q35218614 | New challenges in modern vaccinology |
| Q38646923 | New insights into the immunopathology and control of dengue virus infection |
| Q38596321 | Next generation dengue vaccines: A review of the preclinical development pipeline |
| Q28656158 | No effect of insecticide treated curtain deployment on aedes infestation in a cluster randomized trial in a setting of low dengue transmission in Guantanamo, Cuba |
| Q38904898 | Novel vaccination approach for dengue infection based on recombinant immune complex universal platform |
| Q36816140 | Novel vaccine strategies against emerging viruses |
| Q36895813 | Original antigenic sin in dengue revisited |
| Q58805757 | Oviposition Deterrent Efficacy and Characteristics of a Botanical Natural Product, (L.) Oil-Alginate Beads, against (L.) |
| Q38636217 | Paradoxical role of antibodies in dengue virus infections: considerations for prophylactic vaccine development |
| Q28729784 | Patterns of cellular immunity associated with experimental infection with rDEN2Δ30 (Tonga/74) supports its suitability as a human DENV challenge strain |
| Q37694849 | Persistence of Th1/Tc1 responses one year after tetravalent dengue vaccination in adults and adolescents in Singapore |
| Q33773563 | Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United States |
| Q91704346 | Phenotype and functionality of follicular helper T cells in patients with acute dengue infection |
| Q34746139 | Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies |
| Q40136145 | Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies. |
| Q37683785 | Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand |
| Q38664198 | Points for Consideration for dengue vaccine introduction - recommendations by the Dengue Vaccine Initiative |
| Q26247399 | Potent Allosteric Dengue Virus NS5 Polymerase Inhibitors: Mechanism of Action and Resistance Profiling |
| Q40040450 | Potent Plasmablast-Derived Antibodies Elicited by the National Institutes of Health Dengue Vaccine |
| Q34080726 | Potential opportunities and perils of imperfect dengue vaccines. |
| Q37666763 | Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus |
| Q40148624 | Preclinical development of a dengue tetravalent recombinant subunit vaccine: Immunogenicity and protective efficacy in nonhuman primates |
| Q59209121 | Predatory efficiency of the copepod Megacyclops formosanus and toxic effect of the red alga Gracilaria firma-synthesized silver nanoparticles against the dengue vector Aedes aegypti |
| Q35221318 | Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort |
| Q38202176 | Preparing for dengue vaccine introduction in ASEAN countries: recommendations from the first ADVA regional workshop |
| Q21562244 | Preparing for dengue vaccine introduction: recommendations from the 1st dengue v2V International Meeting |
| Q38368332 | Prevention and Control Strategies to Counter Dengue Virus Infection |
| Q28729782 | Prevention and control of dengue-the light at the end of the tunnel |
| Q38871575 | Production of a Recombinant Dengue Virus 2 NS5 Protein and Potential Use as a Vaccine Antigen |
| Q38794583 | Progress towards understanding the pathogenesis of dengue hemorrhagic fever. |
| Q35836631 | Prospective cohort study with active surveillance for fever in four dengue endemic countries in Latin America |
| Q30235612 | Prospects for a Zika Virus Vaccine |
| Q40191440 | Prospects for a dengue vaccine: progress and pitfalls. |
| Q35898318 | Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy |
| Q33414156 | Protection against dengue virus infection in mice by administration of antibodies against modified nonstructural protein 1. |
| Q38731663 | Protective and immunological behavior of chimeric yellow fever dengue vaccine |
| Q40166759 | Protective immune responses to dengue virus infection and vaccines: perspectives from the field to the bench |
| Q34999848 | Public acceptance and willingness-to-pay for a future dengue vaccine: a community-based survey in Bandung, Indonesia |
| Q34351411 | QTL mapping of genome regions controlling temephos resistance in larvae of the mosquito Aedes aegypti |
| Q38266413 | RNA-based viral vectors |
| Q25202252 | Rapid and Non-destructive Detection and Identification of Two Strains of Wolbachia in Aedes aegypti by Near-Infrared Spectroscopy |
| Q27334248 | Rational design of a live attenuated dengue vaccine: 2'-o-methyltransferase mutants are highly attenuated and immunogenic in mice and macaques |
| Q26825426 | Recent Advances in Dengue: Relevance to Puerto Rico |
| Q38605203 | Recent advances in dengue pathogenesis and clinical management |
| Q92859173 | Recent advances in understanding dengue |
| Q38303232 | Recent progress in dengue vaccine development |
| Q51782806 | Recombinant Zika virus envelope protein elicited protective immunity against Zika virus in immunocompetent mice. |
| Q39028302 | Recombinant lipidated dengue-4 envelope protein domain III elicits protective immunity |
| Q47681827 | Redefining priorities towards graded travel-related infectious disease research |
| Q36799290 | Redesign of a cross-reactive antibody to dengue virus with broad-spectrum activity and increased in vivo potency |
| Q37109553 | Reduced risk of disease during postsecondary dengue virus infections |
| Q58759739 | Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning |
| Q40185164 | Refolding of a fully functional flavivirus methyltransferase revealed that S-adenosyl methionine but not S-adenosyl homocysteine is copurified with flavivirus methyltransferase |
| Q38974932 | Repurposing of prochlorperazine for use against dengue virus infection |
| Q26825672 | Reviewing dengue: still a neglected tropical disease? |
| Q38174301 | Revisiting dengue virus-host cell interaction: new insights into molecular and cellular virology |
| Q92689689 | Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial |
| Q35034240 | Role of humoral versus cellular responses induced by a protective dengue vaccine candidate |
| Q26700096 | Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials |
| Q36024479 | Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial |
| Q49833104 | Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial |
| Q39468688 | Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study |
| Q36288109 | Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study |
| Q40231133 | Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study |
| Q40235135 | Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. |
| Q52684747 | Safety issues from a Phase 3 clinical trial of a live-attenuated chimeric yellow fever tetravalent dengue vaccine. |
| Q38232097 | Safety, immunogenicity and efficacy of a recombinant tetravalent dengue vaccine: a meta-analysis of randomized trials. |
| Q90733120 | Seeking Flavivirus Cross-Protective Immunity |
| Q35250382 | Sensitivity and specificity of a novel classifier for the early diagnosis of dengue |
| Q98164941 | Sequential immunization induces strong and broad immunity against all four dengue virus serotypes |
| Q34496118 | Seroprevalence of neutralizing antibodies against dengue virus in two localities in the state of Morelos, Mexico |
| Q37553822 | Silencing sexually transmitted infections: topical siRNA-based interventions for the prevention of HIV and HSV |
| Q33709817 | Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control |
| Q35557524 | Site-specific characterization of envelope protein N-glycosylation on Sanofi Pasteur's tetravalent CYD dengue vaccine. |
| Q61053717 | Small molecules targeting the flavivirus E protein with broad-spectrum activity and antiviral efficacy in vivo |
| Q37677793 | Socially structured human movement shapes dengue transmission despite the diffusive effect of mosquito dispersal |
| Q36332097 | Socioeconomic and environmental determinants of dengue transmission in an urban setting: An ecological study in Nouméa, New Caledonia |
| Q28656178 | Spatiotemporal distribution of dengue vectors & identification of high risk zones in district Sonitpur, Assam, India |
| Q38773323 | Status of vaccine research and development of vaccines for dengue |
| Q104617064 | Stimulation of B Cell Immunity in Flavivirus-Naive Individuals by the Tetravalent Live Attenuated Dengue Vaccine TV003 |
| Q24740325 | Structural basis of potent Zika–dengue virus antibody cross-neutralization |
| Q26700120 | Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope |
| Q40205459 | Stumbles on the path to dengue control |
| Q56355933 | Successful Vaccines |
| Q35077611 | Synthetic 1,4-pyran naphthoquinones are potent inhibitors of dengue virus replication |
| Q92909202 | Systematic review of dengue vaccine efficacy |
| Q26782580 | Systems Biology Approach for Cancer Vaccine Development and Evaluation |
| Q66679253 | T Cell Responses Induced by DNA Vaccines Based on the DENV2 E and NS1 Proteins in Mice: Importance in Protection and Immunodominant Epitope Identification |
| Q38631171 | T cell immunity to dengue virus and implications for vaccine design. |
| Q33414009 | T-cell immunity to infection with dengue virus in humans |
| Q24288867 | Tackling dengue fever: Current status and challenges |
| Q38923188 | Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease |
| Q40170464 | Tetravalent dengue DIIIC protein together with alum and ODN elicits a Th1 response and neutralizing antibodies in mice |
| Q26700056 | The Cellular Bases of Antibody Responses during Dengue Virus Infection |
| Q26995782 | The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response |
| Q92756077 | The Dengue ED3 Dot Assay, a Novel Serological Test for the Detection of Denguevirus Type-Specific Antibodies and Its Application in a Retrospective Seroprevalence Study |
| Q54557957 | The Dengue Virus Replication Complex: From RNA Replication to Protein-Protein Interactions to Evasion of Innate Immunity. |
| Q59360089 | The Development of Peptide-based Antimicrobial Agents against Dengue Virus |
| Q36776077 | The Effect of Temperature on Wolbachia-Mediated Dengue Virus Blocking in Aedes aegypti |
| Q28954848 | The RNAi pathway plays a small part in Wolbachia-mediated blocking of dengue virus in mosquito cells |
| Q27332223 | The Spread of Dengue in an Endemic Urban Milieu--The Case of Delhi, India |
| Q55432397 | The US Military Commitment to Vaccine Development: A Century of Successes and Challenges. |
| Q47558217 | The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. |
| Q33624593 | The contribution of vaccination to global health: past, present and future |
| Q42987133 | The dengue human challenge model: has the time come to accept this challenge? |
| Q26314683 | The dengue vaccine pipeline: Implications for the future of dengue control |
| Q35034544 | The effects of vector movement and distribution in a mathematical model of dengue transmission |
| Q24628768 | The global distribution and burden of dengue |
| Q34989348 | The high-affinity human IgG receptor Fc gamma receptor I (FcγRI) is not associated with vascular leakage of dengue |
| Q34992520 | The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes |
| Q40205673 | The human dengue challenge experience at the Walter Reed Army Institute of Research |
| Q58569778 | The immune response against flaviviruses |
| Q38176451 | The introduction of new vaccines into developing countries. V: Will we lose a decade or more in the introduction of dengue vaccines to developing countries? |
| Q40109446 | The live attenuated dengue vaccine TV003 elicits complete protection against dengue in a human challenge model |
| Q38994574 | The mechanistic role of antibodies to dengue virus in protection and disease pathogenesis |
| Q35236379 | The protein DIIIC-2, aggregated with a specific oligodeoxynucleotide and adjuvanted in alum, protects mice and monkeys against DENV-2. |
| Q38284671 | The relevance of dengue virus genotypes surveillance at country level before vaccine approval |
| Q33676847 | The role of the mosquito in a dengue human infection model |
| Q37135489 | The successful induction of T-cell and antibody responses by a recombinant measles virus-vectored tetravalent dengue vaccine provides partial protection against dengue-2 infection. |
| Q34614953 | The synergistic effect of combined immunization with a DNA vaccine and chimeric yellow fever/dengue virus leads to strong protection against dengue |
| Q35069160 | The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein |
| Q26865102 | The yellow fever 17D virus as a platform for new live attenuated vaccines |
| Q38149195 | Therapeutic antibodies as a treatment option for dengue fever |
| Q34607919 | Therapeutic efficacy of antibodies lacking Fcγ receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. |
| Q37230310 | Three-Month Real-Time Dengue Forecast Models: An Early Warning System for Outbreak Alerts and Policy Decision Support in Singapore |
| Q33854218 | Time-varying, serotype-specific force of infection of dengue virus |
| Q91173745 | Tracking the polyclonal neutralizing antibody response to a dengue virus serotype 1 type-specific epitope across two populations in Asia and the Americas |
| Q35097106 | Transmission-blocking antibodies against mosquito C-type lectins for dengue prevention |
| Q45323668 | Transplantation of a quaternary structure neutralizing antibody epitope from dengue virus serotype 3 into serotype 4. |
| Q28074355 | Trends in clinical trials of dengue vaccine |
| Q38540058 | Trials and tribulations on the path to developing a dengue vaccine |
| Q91741475 | Two Is Better Than One: Evidence for T-Cell Cross-Protection Between Dengue and Zika and Implications on Vaccine Design |
| Q33744074 | Type I interferon signals in macrophages and dendritic cells control dengue virus infection: implications for a new mouse model to test dengue vaccines |
| Q27011587 | Understanding the dengue viruses and progress towards their control |
| Q38126179 | Urbanization and geographic expansion of zoonotic arboviral diseases: mechanisms and potential strategies for prevention |
| Q40053434 | Use of a Recombinant Gamma-2 Herpesvirus Vaccine Vector against Dengue Virus in Rhesus Monkeys |
| Q59354478 | Using a virion assembly-defective dengue virus as a vaccine approach |
| Q34238916 | Utility, limitations, and future of non-human primates for dengue research and vaccine development |
| Q37184768 | Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles |
| Q40197584 | Vaccination strategies for SIR vector-transmitted diseases. |
| Q27014663 | Vaccine-mediated immunity against dengue and the potential for long-term protection against disease |
| Q28077521 | Vaccines and immunization strategies for dengue prevention |
| Q27007529 | Vaccines for the 21st century |
| Q37096221 | Vaccines for viral hemorrhagic fevers--progress and shortcomings |
| Q39172722 | Vaccines licensed and in clinical trials for the prevention of dengue |
| Q35195545 | Variability in dengue titer estimates from plaque reduction neutralization tests poses a challenge to epidemiological studies and vaccine development |
| Q33413903 | Vascular events in viral hemorrhagic fevers: a comparative study of dengue and hantaviruses |
| Q40261818 | Vector biology prospects in dengue research |
| Q58367215 | Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials |
| Q36082908 | Viral kinetics of primary dengue virus infection in non-human primates: a systematic review and individual pooled analysis |
| Q34262245 | Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine |
| Q36365735 | Viruses acquired abroad: what does the primary care physician need to know? |
| Q47232816 | Vivo-morpholino oligomers strongly inhibit dengue virus replication and production. |
| Q92538927 | Wanted Dead or Alive: A Correlate of Protection Against Dengue Virus |
| Q38674884 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vac |
| Q38157725 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Challenges of a Dengue Vaccine |
| Q40047872 | Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner |
| Q40245518 | Will people change their vector-control practices in the presence of an imperfect dengue vaccine? |
| Q35675701 | Wolbachia Reduces the Transmission Potential of Dengue-Infected Aedes aegypti |
| Q39008654 | Wolbachia: The selfish Trojan Horse in dengue control |
| Q26261644 | Zika virus disease: a current review of the literature |
Search more.